Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today the first two presentations of its AI-enabled drug discovery platform at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The posters showcase Noetik’s OCTO foundation model of cell and tissue biology and demonstrate for the first time the application of OCTO to therapeutics discovery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107864136/en/
Example results from a cell teleporting experiment. Here, we take a ”virtual CD8 T cell” expressing only CD3 and CD8 and teleport it to see what its predicted gene expression will be in the context of each tumor and TME neighborhood in the tissue. (Graphic: Business Wire)
“Noetik’s platform brings together one of the largest multimodal spatial datasets of human tumor biology, generated in-house at Noetik labs, with custom-built self-supervised models that are trained at a scale to unlock the complexities of biology. The work at SITC showcases, for the first time, how we can use these models as powerful engines for drug discovery,” said Lacey Padron, Ph.D., Chief Technical Officer of Noetik and presenter.
SITC, a leading member-driven organization dedicated to improving cancer patient outcomes by advancing cancer immunotherapy, will host its 2024 Annual Meeting from November 6th to 10th at the George R. Brown Convention Center in Houston. The abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC).
Details on Noetik’s poster presentations at SITC are as follows:
Title: Foundation Models of Cell and Tissue Biology Enabled by Custom Scaled Data Generation: Insights from 1000 Lung Tumor Samples
Abstract Number: 1231
Date: Friday, November 8
Location: Houston George R. Brown Convention Center - Level 1 - Exhibit Halls AB or online at https://jitc.bmj.com/content/12/Suppl_2/A1372
Title: Multimodal foundation model of human lung tumors identifies tertiary lymphoid structures (TLS) and reveals novel therapeutic targets that promote anti-tumor immune response
Abstract Number: 861
Date: Friday, November 8
Location: Houston George R. Brown Convention Center - Level 1 - Exhibit Halls AB or online at https://jitc.bmj.com/content/12/Suppl_2/A975
To learn more about OCTO, visit https://www.noetik.ai/octo
To learn more about our comprehensive patient dataset, visit https://www.noetik.ai/lungcanceratlas
About Noetik
Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision therapies. The company is based in San Francisco, CA. For more information, visit https://www.noetik.ai/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107864136/en/
Contacts
Nicole Snell, Ph.D.
info@noetik.ai
